Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. Chief Medical Officer Craig Eagle reported routine equity compensation activity as several restricted stock unit awards vested on April 1, 2026. He exercised RSUs to acquire a total of 11,400 shares of common stock at an exercise price of $0.00 per share.
To satisfy related tax obligations, 5,779 shares of common stock were retained by the company at $91.15 per share, as described in the footnotes, rather than sold on the open market. Following these transactions, Eagle directly holds 72,001 shares of Guardant Health common stock.
Guardant Health Chief Technology Officer Darya Chudova reported routine equity compensation activity tied to vesting restricted stock units. On April 1, 2026, she acquired a total of 13,029 shares of Guardant Health common stock through the exercise and conversion of multiple restricted stock unit awards at a stated price of $0.00 per share.
To cover tax withholding obligations upon vesting, 7,005 shares were retained by the company at a price of $91.15 per share, as described in the footnotes. After these compensation-related transactions and tax withholding, Chudova directly holds 70,376 shares of Guardant Health common stock.
Guardant Health, Inc. Chief Financial Officer Michael Brian Bell exercised restricted stock units into common shares and had shares withheld for taxes. On April 1, 2026, he converted multiple restricted stock unit awards into a total of 12,777 shares of common stock at a conversion price of $0.00 per share.
In a related tax-withholding transaction, 6,869 common shares were retained by the company at $91.15 per share to satisfy tax liabilities tied to the RSU vesting. After these transactions, Bell directly held 49,509 shares of Guardant Health common stock, reflecting routine equity compensation activity rather than an open-market trade.
Guardant Health, Inc. Co-Chief Executive Officer AmirAli Talasaz reported routine equity compensation activity involving restricted stock units (RSUs) and related common stock on March 31 and April 1, 2026. Several RSU awards vested and were converted into shares of common stock held largely through the Talasaz and Eskandari 2017 Family Trust. In connection with these vestings, a total of 18,515 shares of common stock were withheld by the company at prices of $92.37 and $91.15 per share to satisfy tax withholding obligations, rather than sold in open-market transactions. Following these transactions, the family trust held 2,146,504 shares of Guardant Health common stock, while Talasaz also retained a substantial number of unvested RSUs directly.
Guardant Health, Inc. co-Chief Executive Officer Helmy Eltoukhy reported routine equity compensation activity involving restricted stock units and related common stock. On March 31 and April 1, 2026, multiple restricted stock unit awards converted into an aggregate of tens of thousands of shares of common stock at a $0.00 exercise price.
To cover associated tax obligations upon these vesting events, a total of 18,515 shares of common stock were retained by the company at prices of $92.37 and $91.15 per share, characterized as tax-withholding dispositions rather than open-market sales. Following these transactions, a revocable trust associated with Eltoukhy held 2,112,919 shares of common stock, and he directly held 68,011 restricted stock units. The filing reflects compensation-related vesting and tax withholding, not discretionary market trading.
Guardant Health director Steve E. Krognes acquired 155 shares of Common Stock through the vesting and exercise of Restricted Stock Units. The transaction occurred on March 31, 2026 at an exercise price of $0.00 per share, reflecting a routine equity-compensation event rather than an open-market purchase.
The 155 Restricted Stock Units converted into 155 shares of Common Stock, increasing his direct Common Stock holdings to 19,208 shares following the transaction. He also continues to hold 463 Restricted Stock Units after this vesting. The underlying award was originally granted on August 9, 2022 and vests over four years, with 25% vesting on June 30, 2023 and the remaining 75% vesting in substantially equal monthly installments over the subsequent three years.
Guardant Health Inc Amendment No. 4 to a Schedule 13G/A reports that The Vanguard Group holds 0 shares and 0% of Guardant Health common stock following an internal realignment. The filing cites SEC Release No. 34-39538 and states Vanguard subsidiaries will report separately.
Guardant Health director Roberto Mignone reported the vesting and settlement of 264 restricted stock units into an equal number of common shares at a price of $0.00 per share, reflecting a routine equity compensation event rather than an open-market trade.
After this derivative exercise, Mignone directly holds 4,487 shares of common stock and 8,184 restricted stock units. The vested RSUs come from an award granted on November 8, 2024 that vests 25% on the one-year anniversary of October 21, 2024, with the remaining 75% vesting monthly over the following three years.
Guardant Health director Tariq Musa reported an open-market sale of 348 shares of Guardant Health common stock on March 18, 2026, at an average price of $88.09 per share. After this transaction, he directly holds 8,394 shares of the company’s stock.
Guardant Health director Manuel Hidalgo Medina exercised restricted stock units into common shares as part of his equity compensation. On March 17, 2026, 232 restricted stock units converted into 232 shares of common stock at a stated price of $0.00 per share, raising his direct common stock holdings to 1,425 shares. The award originated from a grant on July 17, 2024 that vests over four years, with 25% vesting on the one-year anniversary and the remaining 75% vesting monthly over the following three years.